Pfizer's new hemophilia treatment drug Mataximab's application for market launch in China has been accepted
楚一帆
发表于 2024-8-13 10:09:17
220
0
0
On August 13th, the official website of the Drug Evaluation Center (CDE) of the China National Medical Products Administration (NMPA) announced that the Class 1 therapeutic biological product Mataximab Injection, declared by Pfizer, has been approved for listing in China. Marstacimab is a novel hemophilia treatment drug developed by Pfizer, which only requires subcutaneous injection once a week.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Honda accelerates its electrification layout in China, with joint ventures intensively deploying electric vehicles
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- Nvidia expands in China against the trend, attracting talent and adding hundreds of R&D personnel in one year
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- Apple is rumored to have preliminary discussions with Tencent and ByteDance to consider embedding their AI models into iPhones sold in China
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
- Sanofi's BTK inhibitor is declared for market in China
